FLT4 and heart failure: Moreover, administration of lymphangiogenic factors such as VEGFCC156S, a point mutant that is a specific VEGFR3 ligand, to further facilitate lymphangiogenesis and improve lymphatic function in rodent model of heart failure demonstrated beneficial effects, as we discuss in greater detail in another section of this review article, highlighting the potential of targeting lymphatics for the treatment of heart failure (30, 31).